NASDAQ:LNTH Lantheus (LNTH) Stock Forecast, Price & News $88.78 +1.97 (+2.27%) (As of 06/8/2023 ET) Add Compare Share Share Today's Range$86.50▼$89.3250-Day Range$80.72▼$99.6552-Week Range$47.46▼$100.85Volume703,074 shsAverage Volume1.02 million shsMarket Capitalization$6.07 billionP/E RatioN/ADividend YieldN/APrice Target$121.83 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Lantheus MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside37.2% Upside$121.83 Price TargetShort InterestHealthy5.07% of Float Sold ShortDividend StrengthN/ASustainability-1.67Upright™ Environmental ScoreNews Sentiment0.78Based on 6 Articles This WeekInsider TradingSelling Shares$9.29 M Sold Last QuarterProj. Earnings Growth10.19%From $5.20 to $5.73 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.64 out of 5 starsMedical Sector64th out of 981 stocksDiagnostic Substances Industry1st out of 15 stocks 3.5 Analyst's Opinion Consensus RatingLantheus has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $121.83, Lantheus has a forecasted upside of 37.2% from its current price of $88.78.Amount of Analyst CoverageLantheus has only been the subject of 1 research reports in the past 90 days. Previous Next 4.0 Short Interest Percentage of Shares Shorted5.07% of the float of Lantheus has been sold short.Short Interest Ratio / Days to CoverLantheus has a short interest ratio ("days to cover") of 3.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Lantheus has recently decreased by 6.87%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldLantheus does not currently pay a dividend.Dividend GrowthLantheus does not have a long track record of dividend growth. Previous Next 4.2 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreLantheus has received a 61.07% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Clinical research services for cancer", "Diagnostic radiopharmaceuticals", and "Therapeutic radiopharmaceuticals" products. See details.Environmental SustainabilityThe Environmental Impact score for Lantheus is -1.67. Previous Next 2.7 News and Social Media Coverage News SentimentLantheus has a news sentiment score of 0.78. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.51 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Lantheus this week, compared to 7 articles on an average week.Search InterestOnly 32 people have searched for LNTH on MarketBeat in the last 30 days. This is a decrease of -38% compared to the previous 30 days.MarketBeat Follows12 people have added Lantheus to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Lantheus insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $9,294,442.00 in company stock.Percentage Held by InsidersOnly 1.50% of the stock of Lantheus is held by insiders.Percentage Held by Institutions97.62% of the stock of Lantheus is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Lantheus are expected to grow by 10.19% in the coming year, from $5.20 to $5.73 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Lantheus is -286.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Lantheus is -286.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioLantheus has a P/B Ratio of 13.66. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Lantheus (NASDAQ:LNTH) StockLantheus Holdings, Inc. engages in the provision of diagnostic imaging and nuclear medicine products. The firm develops products that help healthcare professionals in patient management and outcomes and assists clinicians with the detection of cardiovascular disease. It operates through the U.S. and International geographical segments. The U.S. segment produces and markets products, radiopharmacies, PMFs, integrated delivery networks, hospitals, clinics, and group practices throughout the United States. The International segment offers direct distribution in Canada and Puerto Rico, third-party distribution in Europe, Canada, Australia, Asia-Pacific, and Latin America, and the EXINI business in Sweden. The company was founded in 1956 and is headquartered in Bedford, MA.Read More Receive LNTH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Lantheus and its competitors with MarketBeat's FREE daily newsletter. Email Address LNTH Stock News HeadlinesJune 3, 2023 | benzinga.comLantheus Holdings Stock (NASDAQ:LNTH), Insider Trading ActivityJune 1, 2023 | msn.comJMP Securities Reiterates Lantheus Holdings (LNTH) Market Outperform RecommendationJune 8, 2023 | Behind the Markets (Ad)Laser breakthrough could send stock soaring 2,467%Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...June 1, 2023 | markets.businessinsider.comAnalyst Ratings for Lantheus HoldingsJune 1, 2023 | msn.comLantheus Holdings (LNTH) is an Incredible Growth Stock: 3 Reasons WhyMay 30, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: PDS Biotechnology (PDSB) and Lantheus (LNTH)May 30, 2023 | markets.businessinsider.comB.Riley Financial Remains a Buy on Lantheus (LNTH)May 28, 2023 | americanbankingnews.comLantheus Holdings, Inc. (NASDAQ:LNTH) Receives $122.20 Consensus Target Price from BrokeragesJune 8, 2023 | Behind the Markets (Ad)Laser breakthrough could send stock soaring 2,467%Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...May 25, 2023 | fool.comLantheus (NASDAQ: LNTH)May 25, 2023 | msn.com3 Stocks Stocks Institutional Investors Can’t Get Enough ofMay 24, 2023 | americanbankingnews.comInsider Selling: Lantheus Holdings, Inc. (NASDAQ:LNTH) President Sells 1,500 Shares of StockMay 22, 2023 | finance.yahoo.comIs Lantheus Holdings (LNTH) a Buy as Wall Street Analysts Look Optimistic?May 22, 2023 | finance.yahoo.comZacks.com featured highlights Carrols Restaurant, Celsius Holdings, VirTra, Interdigital and LantheusMay 20, 2023 | americanbankingnews.comLantheus Holdings, Inc. (NASDAQ:LNTH) CFO Sells $993,600.00 in StockMay 19, 2023 | finance.yahoo.com5 Stocks With Recent Price Strength to Maximize Your ReturnsMay 19, 2023 | americanbankingnews.comInsider Selling: Lantheus Holdings, Inc. (NASDAQ:LNTH) CAO Sells 385 Shares of StockMay 17, 2023 | finance.yahoo.comWall Street Analysts Believe Lantheus Holdings (LNTH) Could Rally 25.73%: Here's is How to TradeMay 17, 2023 | americanbankingnews.comDaniel Niedzwiecki Sells 6,113 Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) StockMay 16, 2023 | finance.yahoo.com3 Reasons Growth Investors Will Love Lantheus Holdings (LNTH)May 15, 2023 | msn.comLantheus Holdings's Return On Capital Employed OverviewMay 13, 2023 | americanbankingnews.comLantheus (NASDAQ:LNTH) Rating Increased to Buy at StockNews.comMay 9, 2023 | finance.yahoo.comLantheus Holdings, Inc. (LNTH) is Attracting Investor Attention: Here is What You Should KnowMay 9, 2023 | americanbankingnews.comLantheus (NASDAQ:LNTH) PT Raised to $127.00 at SVB SecuritiesMay 8, 2023 | finance.yahoo.comThe 13% return this week takes Lantheus Holdings' (NASDAQ:LNTH) shareholders three-year gains to 635%May 8, 2023 | americanbankingnews.comLantheus (NASDAQ:LNTH) Given New $130.00 Price Target at JMP SecuritiesMay 8, 2023 | americanbankingnews.comLantheus (NASDAQ:LNTH) Price Target Raised to $125.00See More Headlines LNTH Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart LNTH Company Calendar Last Earnings5/04/2023Today6/08/2023Next Earnings (Estimated)8/03/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Diagnostic substances Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:LNTH CUSIPN/A CIK1521036 Webwww.lantheus.com Phone(978) 671-8001Fax978-671-8860Employees612Year FoundedN/APrice Target and Rating Average Stock Price Forecast$121.83 High Stock Price Forecast$130.00 Low Stock Price Forecast$104.00 Forecasted Upside/Downside+37.6%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($0.31) Trailing P/E RatioN/A Forward P/E Ratio17.03 P/E GrowthN/ANet Income$28.07 million Net Margins-1.72% Pretax Margin-4.12% Return on Equity58.60% Return on Assets25.72% Debt Debt-to-Equity Ratio1.25 Current Ratio2.80 Quick Ratio2.65 Sales & Book Value Annual Sales$935.06 million Price / Sales6.47 Cash Flow$4.67 per share Price / Cash Flow18.95 Book Value$6.50 per share Price / Book13.62Miscellaneous Outstanding Shares68,330,000Free Float67,308,000Market Cap$6.05 billion OptionableOptionable Beta0.68 Key ExecutivesMary Anne HeinoChief Executive Officer & DirectorPaul BlanchfieldPresidentRobert J. MarshallChief Financial Officer & TreasurerSimon RobinsonSenior VP-Research & Pharmaceutical DevelopmentIryna TeslenkoVice President-Clinical DevelopmentKey CompetitorsQuidelOrthoNASDAQ:QDELNeogenNASDAQ:NEOGIntellia TherapeuticsNASDAQ:NTLAMyriad GeneticsNASDAQ:MYGNCelldex TherapeuticsNASDAQ:CLDXView All CompetitorsInsiders & InstitutionsLevel Four Advisory Services LLCBought 5,392 shares on 6/5/2023Ownership: 0.008%Ontario Teachers Pension Plan BoardBought 10,962 shares on 6/1/2023Ownership: 0.016%Prelude Capital Management LLCBought 1,549 shares on 6/1/2023Ownership: 0.009%ProShare Advisors LLCSold 896 shares on 5/26/2023Ownership: 0.018%Legato Capital Management LLCBought 851 shares on 5/25/2023Ownership: 0.016%View All Insider TransactionsView All Institutional Transactions LNTH Stock - Frequently Asked Questions Should I buy or sell Lantheus stock right now? 6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Lantheus in the last twelve months. There are currently 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" LNTH shares. View LNTH analyst ratings or view top-rated stocks. What is Lantheus' stock price forecast for 2023? 6 analysts have issued 1 year target prices for Lantheus' shares. Their LNTH share price forecasts range from $104.00 to $130.00. On average, they anticipate the company's stock price to reach $121.83 in the next twelve months. This suggests a possible upside of 37.6% from the stock's current price. View analysts price targets for LNTH or view top-rated stocks among Wall Street analysts. How have LNTH shares performed in 2023? Lantheus' stock was trading at $50.96 at the beginning of the year. Since then, LNTH stock has increased by 73.8% and is now trading at $88.55. View the best growth stocks for 2023 here. When is Lantheus' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 3rd 2023. View our LNTH earnings forecast. How were Lantheus' earnings last quarter? Lantheus Holdings, Inc. (NASDAQ:LNTH) released its earnings results on Thursday, May, 4th. The medical equipment provider reported $1.37 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.21 by $0.16. The medical equipment provider earned $300.78 million during the quarter, compared to analyst estimates of $280.65 million. Lantheus had a negative net margin of 1.72% and a positive trailing twelve-month return on equity of 58.60%. What ETFs hold Lantheus' stock? ETFs with the largest weight of Lantheus (NASDAQ:LNTH) stock in their portfolio include Invesco DWA Healthcare Momentum ETF (PTH), Harbor Health Care ETF (MEDI), Innovator IBD 50 ETF (FFTY), Invesco S&P MidCap Momentum ETF (XMMO), SPDR S&P Health Care Equipment ETF (XHE), Invesco S&P MidCap Quality ETF (XMHQ), Pacer Lunt MidCap Multi-Factor Alternator ETF (PAMC) and Invesco S&P MidCap 400 Pure Growth ETF (RFG). What guidance has Lantheus issued on next quarter's earnings? Lantheus updated its second quarter 2023 earnings guidance on Thursday, May, 4th. The company provided EPS guidance of $1.25-$1.33 for the period, compared to the consensus EPS estimate of $1.21. The company issued revenue guidance of $300.00 million-$310.00 million, compared to the consensus revenue estimate of $285.93 million. What is Mary Anne Heino's approval rating as Lantheus' CEO? 4 employees have rated Lantheus Chief Executive Officer Mary Anne Heino on Glassdoor.com. Mary Anne Heino has an approval rating of 51% among the company's employees. This puts Mary Anne Heino in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Lantheus own? Based on aggregate information from My MarketBeat watchlists, some companies that other Lantheus investors own include (MBBYF) (MBBYF), Energy Transfer (ET), Paratek Pharmaceuticals (PRTK), Catalyst Pharmaceuticals (CPRX), Amicus Therapeutics (FOLD), Anavex Life Sciences (AVXL), Exelixis (EXEL), Gerdau (GGB), Pieris Pharmaceuticals (PIRS) and Abeona Therapeutics (ABEO). When did Lantheus IPO? (LNTH) raised $75 million in an IPO on Thursday, June 25th 2015. The company issued 7,900,000 shares at $8.50-$10.50 per share. Citigroup, Jefferies, RBC Capital Markets and Wells Fargo Securities acted as the underwriters for the IPO and Baird was co-manager. What is Lantheus' stock symbol? Lantheus trades on the NASDAQ under the ticker symbol "LNTH." Who are Lantheus' major shareholders? Lantheus' stock is owned by many different retail and institutional investors. Top institutional investors include BlackRock Inc. (11.43%), State Street Corp (3.40%), Hood River Capital Management LLC (2.39%), Assenagon Asset Management S.A. (2.15%), Dimensional Fund Advisors LP (2.03%) and Geode Capital Management LLC (1.97%). Insiders that own company stock include Andrea Sabens, Brian A Markison, Carol Walker, Daniel Niedzwiecki, Etienne Montagut, Gerard Ber, Heinz Christoph Maeusli, John J Bolla, Mary Anne Heino, Michael P Duffy, Michael P Duffy, Paul Blanchfield, Robert J Jr Marshall and Sam R Leno. View institutional ownership trends. How do I buy shares of Lantheus? Shares of LNTH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Lantheus' stock price today? One share of LNTH stock can currently be purchased for approximately $88.55. How much money does Lantheus make? Lantheus (NASDAQ:LNTH) has a market capitalization of $6.05 billion and generates $935.06 million in revenue each year. The medical equipment provider earns $28.07 million in net income (profit) each year or ($0.31) on an earnings per share basis. How many employees does Lantheus have? The company employs 612 workers across the globe. How can I contact Lantheus? Lantheus' mailing address is 331 TREBLE COVE ROAD, NORTH BILLERICA MA, 01862. The official website for the company is www.lantheus.com. The medical equipment provider can be reached via phone at (978) 671-8001, via email at ir@lantheus.com, or via fax at 978-671-8860. This page (NASDAQ:LNTH) was last updated on 6/8/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lantheus Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.